From: Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine
Participants with ≥ 1 ISRs
Total, n (%)
N
1326
IS pain
108 (8.1)
Unspecified ISRs
103 (7.8)
IS erythema
62 (4.7)
IS pruritus
30 (2.3)
IS bruising
25 (1.9)
IS rash
18 (1.4)
IS hematoma
14 (1.1)